Ruthenium complexes for breast cancer therapy

References

Abbasi, M.; Yaqoob, M.; Haque, R. A.; Iqbal, M. A. Potential of gold candidates against human colon cancer. Mini Rev. Med. Chem. 2021, 21(1), 69–78; https://doi.org/10.2174/1389557520666200807130721.Search in Google Scholar PubMed

Al Nasr, I. S.; Koko, W. S.; Khan, T. A.; Gürbüz, N.; Özdemir, I.; Hamdi, N. Evaluation of ruthenium (II) N-heterocyclic carbene complexes as enzymatic inhibitory agents with antioxidant, antimicrobial, antiparasitical and antiproliferative activity. Molecules 2023, 28(3), 1359; https://doi.org/10.3390/molecules28031359.Search in Google Scholar PubMed PubMed Central

Alessio, E. Thirty years of the drug candidate NAMI‐A and the myths in the field of ruthenium anticancer compounds: a personal perspective. Eur. J. Inorg. Chem. 2017, 2017(12), 1549–1560; https://doi.org/10.1002/ejic.201600986.Search in Google Scholar

Alessio, E.; Messori, L. NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: a case story in medicinal inorganic chemistry. Molecules 2019, 24(10), 1995; https://doi.org/10.3390/molecules24101995.Search in Google Scholar PubMed PubMed Central

Ashraf, R.; Sarfraz, A.; Taskin-Tok, T.; Iqbal, M. J.; Iqbal, M. A.; Iqbal, J.; Bhatti, H. N.; El-Naggar, M.; Akram, S.; Murshed, M. N.; El Sayed, M. E.; Samir, A. Synthesis, molecular docking and anticancer potential of azolium based salts and their silver complexes: DNA/BSA interaction studies and cell cycle analysis. J. Mol. Liq. 2023, 369, 120921; https://doi.org/10.1016/j.molliq.2022.120921.Search in Google Scholar

Ayipo, Y. O.; Osunniran, W. A.; Mordi, M. N. Metal complexes of β-carboline: advances in anticancer therapeutics. Coord. Chem. Rev. 2021, 432, 213746; https://doi.org/10.1016/j.ccr.2020.213746.Search in Google Scholar

Bashir, K.; Jamil, F.; Iqbal, M. A.; Nazir, S.; Shoukat, U. S.; Bashir, A.; Nasrullah, K.; Rehman, A. U. Detection of different chemical moieties in aqueous media by luminescent Europium as sensor. Rev. Inorg. Chem. 2023; https://doi.org/10.1515/revic-2022-0034.Search in Google Scholar

Bergamo, A.; Sava, G. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Trans. 2011, 40(31), 7817–7823; https://doi.org/10.1039/c0dt01816c.Search in Google Scholar PubMed

Bergamo, A.; Masi, A.; Jakupec, M. A.; Keppler, B. K.; Sava, G. Inhibitory effects of the ruthenium complex KP1019 in models of mammary cancer cell migration and invasion. Met. Base. Drugs 2009, 2009, 681270; https://doi.org/10.1155/2009/681270.Search in Google Scholar PubMed PubMed Central

Bhardwaj, P.; Au, C. C.; Benito-Martin, A.; Ladumor, H.; Oshchepkova, S.; Moges, R.; Brown, K. A. Estrogens and breast cancer: mechanisms involved in obesity-related development, growth and progression. J. Steroid Biochem. Mol. Biol. 2019, 189, 161–170; https://doi.org/10.1016/j.jsbmb.2019.03.002.Search in Google Scholar PubMed PubMed Central

Boyd, M. R. The NCI in vitro anticancer drug discovery screen. In Anticancer drug development guide; Humana Press: Totowa, NJ, 1997; pp. 23–42.10.1007/978-1-4615-8152-9_2Search in Google Scholar

Brown, D. G.; Sanguantrakun, N.; Schulze, B.; Schubert, U. S.; Berlinguette, C. P. Bis (tridentate) ruthenium–terpyridine complexes featuring microsecond excited-state lifetimes. J. Am. Chem. Soc. 2012, 134(30), 12354–12357; https://doi.org/10.1021/ja3039536.Search in Google Scholar PubMed

Bruno, R. D.; Njar, V. C. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg. Med. Chem. 2007, 15(15), 5047–5060; https://doi.org/10.1016/j.bmc.2007.05.046.Search in Google Scholar PubMed PubMed Central

Castonguay, A.; Doucet, C.; Juhas, M.; Maysinger, D. New ruthenium (II)–letrozole complexes as anticancer therapeutics. J. Med. Chem. 2012, 55(20), 8799–8806; https://doi.org/10.1021/jm301103y.Search in Google Scholar PubMed

Chen, Z.-F.; Qin, Q. P.; Qin, J. L.; Zhou, J.; Li, Y. L.; Liu, Y. C.; Liang, H. Water-soluble ruthenium (II) complexes with chiral 4-(2, 3-dihydroxypropyl)-formamide oxoaporphine (FOA): in vitro and in vivo anticancer activity by stabilization of G-Quadruplex DNA, inhibition of telomerase activity, and induction of tumor cell apoptosis. J. Med. Chem. 2015, 58(11), 4771–4789; https://doi.org/10.1021/acs.jmedchem.5b00444.Search in Google Scholar PubMed

Chu, Q.; Vincent, M.; Logan, D.; Mackay, J. A.; Evans, W. K. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2005, 50(3), 355–374; https://doi.org/10.1016/j.lungcan.2005.06.010.Search in Google Scholar PubMed

Coluccia, M.; Sava, G.; Salerno, G.; Bergamo, A.; Pacor, S.; Mestroni, G.; Alessio, E. Efficacy of 5-FU combined to Na [trans-RuCl4 (DMSO) Im], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma. Met. Base. Drugs 1995, 2(4), 195–199; https://doi.org/10.1155/mbd.1995.195.Search in Google Scholar

Coverdale, J. P.; Laroiya-McCarron, T.; Romero-Canelón, I. Designing ruthenium anticancer drugs: what have we learnt from the key drug candidates? Inorganics 2019, 7(3), 31; https://doi.org/10.3390/inorganics7030031.Search in Google Scholar

Desoize, B. Metals and metal compounds in cancer treatment. Anticancer Res. 2004, 24(3A), 1529–1544.Search in Google Scholar

Dickson, N.; Jones, S. F.; Burris, H. A.; Ramanathan, R. K.; Weiss, G. J.; Infante, J. R.; Bendell, J. C.; McCulloch, W.; Von Hoff, D. D. A phase I dose-escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment. J. Clin. Oncol. 2011, 29, 2607; https://doi.org/10.1200/jco.2011.29.15_suppl.2607.Search in Google Scholar

Duan, L.; Fischer, A.; Xu, Y.; Sun, L. Isolated seven-coordinate Ru (IV) dimer complex with [HOHOH]− bridging ligand as an intermediate for catalytic water oxidation. J. Am. Chem. Soc. 2009, 131(30), 10397–10399; https://doi.org/10.1021/ja9034686.Search in Google Scholar PubMed

Dumat, B.; Larsen, A. F.; Wilhelmsson, L. M. Studying Z-DNA and B-to Z-DNA transitions using a cytosine analogue FRET-pair. Nucleic Acids Res. 2016, 44(11), e101; https://doi.org/10.1093/nar/gkw114.Search in Google Scholar PubMed PubMed Central

Dwyer, F.; Gyarfas, E. C.; Rogers, W. P.; Koch, J. H. Biological activity of complex ions. Nature 1952, 170(4318), 190–191; https://doi.org/10.1038/170190a0.Search in Google Scholar PubMed

Dyson, P. J.; Sava, G. Metal-based antitumour drugs in the post genomic era. Dalton Trans. 2006(16), 1929–1933; https://doi.org/10.1039/b601840h.Search in Google Scholar PubMed

Ferraro, M. G.; Piccolo, M.; Misso, G.; Maione, F.; Montesarchio, D.; Caraglia, M.; Paduano, L.; Santamaria, R.; Irace, C. Breast cancer chemotherapeutic options: a general overview on the preclinical validation of a multi-target ruthenium (III) complex lodged in nucleolipid nanosystems. Cells 2020, 9(6), 1412; https://doi.org/10.3390/cells9061412.Search in Google Scholar PubMed PubMed Central

Frik, M.; Martínez, A.; Elie, B. T.; Gonzalo, O.; Ramírez de Mingo, D.; Sanaú, M.; Sánchez-Delgado, R.; Sadhukha, T.; Prabha, S.; Ramos, J. W.; Marzo, I.; Contel, M. In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium (II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. J. Med. Chem. 2014, 57(23), 9995–10012; https://doi.org/10.1021/jm5012337.Search in Google Scholar PubMed PubMed Central

Galanski, M. Recent developments in the field of anticancer platinum complexes. Recent Pat. Anti-Cancer Drug Discov. 2006, 1(2), 285–295; https://doi.org/10.2174/157489206777442287.Search in Google Scholar PubMed

Golbaghi, G.; Castonguay, A. Rationally designed ruthenium complexes for breast cancer therapy. Molecules 2020, 25(2), 265; https://doi.org/10.3390/molecules25020265.Search in Google Scholar PubMed PubMed Central

Golbaghi, G.; Pitard, I.; Lucas, M.; Haghdoost, M. M.; de los Santos, Y. L.; Doucet, N.; Patten, S. A.; Sanderson, J. T.; Castonguay, A. Synthesis and biological assessment of a ruthenium (II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos. Eur. J. Med. Chem. 2020, 188, 112030; https://doi.org/10.1016/j.ejmech.2019.112030.Search in Google Scholar PubMed PubMed Central

Gourdon, L.; Cariou, K.; Gasser, G. Phototherapeutic anticancer strategies with first-row transition metal complexes: a critical review. Chem. Soc. Rev. 2022, 51(3), 1167–1195; https://doi.org/10.1039/d1cs00609f.Search in Google Scholar PubMed

Guedes, A. P. M.; Mello-Andrade, F.; Pires, W. C.; de Sousa, M. A. M.; da Silva, P. F. F.; de Camargo, M. S.; Gemeiner, H.; Amauri, M. A.; Gomes Cardoso, C.; de Melo Reis, P. R.; Silveira-Lacerda, E. d. P.; Batista, A. A. Heterobimetallic Ru (ii)/Fe (ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets. Metallomics 2020, 12(4), 547–561; https://doi.org/10.1039/c9mt00272c.Search in Google Scholar PubMed

Halevas, E.; Pekou, A.; Papi, R.; Mavroidi, B.; Hatzidimitriou, A. G.; Zahariou, G.; Litsardakis, G.; Sagnou, M.; Pelecanou, M.; Pantazaki, A. A. Synthesis, physicochemical characterization and biological properties of two novel Cu (II) complexes based on natural products curcumin and quercetin. J. Inorg. Biochem. 2020, 208, 111083; https://doi.org/10.1016/j.jinorgbio.2020.111083.Search in Google Scholar PubMed

Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, B. K. From bench to bedside–preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis (1H-indazole) ruthenate (III)](KP1019 or FFC14A). J. Inorg. Biochem. 2006, 100(5–6), 891–904; https://doi.org/10.1016/j.jinorgbio.2006.02.013.Search in Google Scholar PubMed

Hartinger, C. G.; Jakupec, M.; Zorbas‐Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P.; Keppler, B. KP1019, a new redox‐active anticancer agent–Preclinical development and results of a clinical phase I study in tumor patients. Chem. Biodivers. 2008, 5(10), 2140–2155; https://doi.org/10.1002/cbdv.200890195.Search in Google Scholar PubMed

Hayat, K.; Shkeel, M.; Iqbal, M. A.; Quah, C. K.; Wong, Q. A.; Nazari, M. V.; Ahamed, M. B. K.; Hameed, S. O-Halogen-substituted arene linked selenium-N-heterocyclic carbene compounds induce significant cytotoxicity: crystal structures and molecular docking studies. J. Organomet. Chem. 2023, 985, 122593; https://doi.org/10.1016/j.jorganchem.2022.122593.Search in Google Scholar

He, X.; Chen, J.; Kandawa-Shultz, M.; Shao, G.; Wang, Y. In vitro and in vivo antitumor activity of novel half-sandwich ruthenium complexes containing quinoline derivative ligands. Dalton Trans. 2023, 52(15), 4728–4736; https://doi.org/10.1039/d2dt03317h.Search in Google Scholar PubMed

Heffeter, P.; Böck, K.; Atil, B.; Reza Hoda, M. A.; Körner, W.; Bartel, C.; Jungwirth, U.; Keppler, B. K.; Micksche, M.; Berger, W.; Koellensperger, G. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J. Biol. Inorg Chem. 2010, 15(5), 737–748; https://doi.org/10.1007/s00775-010-0642-1.Search in Google Scholar PubMed PubMed Central

Huang, H.; Zhang, P.; Chen, H.; Ji, L.; Chao, H. Comparison between polypyridyl and cyclometalated ruthenium (II) complexes: anticancer activities against 2D and 3D cancer models. Chem.--Eur. J. 2015, 21(2), 715–725; https://doi.org/10.1002/chem.201404922.Search in Google Scholar PubMed

Hudej, R.; Miklavcic, D.; Cemazar, M.; Todorovic, V.; Sersa, G.; Bergamo, A.; Sava, G.; Martincic, A.; Scancar, J.; Keppler, B. K.; Turel, I. Modulation of activity of known cytotoxic ruthenium (III) compound (KP418) with hampered transmembrane transport in electrochemotherapy in vitro and in vivo. J. Membr. Biol. 2014, 247(12), 1239–1251; https://doi.org/10.1007/s00232-014-9696-2.Search in Google Scholar PubMed

Iida, J.; Bell-Loncella, E. T.; Purazo, M. L.; Lu, Y.; Dorchak, J.; Clancy, R.; Slavik, J.; Cutler, M. L.; Shriver, C. D. Inhibition of cancer cell growth by ruthenium complexes. J. Transl. Med. 2016, 14(1), 1–10; https://doi.org/10.1186/s12967-016-0797-9.Search in Google Scholar PubMed PubMed Central

Jawiczuk, M.; Kuźmierkiewicz, N.; Nowacka, A. M.; Moreń, M.; Trzaskowski, B. Mechanistic, computational study of alkene-diazene heterofunctional cross-metathesis catalyzed by ruthenium complexes. Organometallics 2023, 2, 146–156; https://doi.org/10.1021/acs.organomet.2c00516.Search in Google Scholar

Joshi, H.; Press, M. F. Molecular oncology of breast cancer. In The Breast; Elsevier: Philadelphia, PA, 2018; p. 282–307.e5.10.1016/B978-0-323-35955-9.00022-2Search in Google Scholar

Júnior, F. S. G.; Silveira, J. A. d. M.; Holanda, T. M.; Marinho, A. D.; Ridnour, L. A.; Wink, D. A.; de Siqueira, R. J. B.; Monteiro, H. S. A.; Sousa, E. H. S. d.; Lopes, L. G. d. F. New nitrosyl ruthenium complexes with combined activities for multiple cardiovascular disorders. Dalton Trans. 2023, 52, 5176–5191; https://doi.org/10.1039/d3dt00059a.Search in Google Scholar PubMed PubMed Central

Kamal, A.; Iqbal, M. A.; Bhatti, H. N. Therapeutic applications of selenium-derived compounds. Rev. Inorg. Chem. 2018, 38(2), 49–76; https://doi.org/10.1515/revic-2018-0008.Search in Google Scholar

Kamal, A.; Muhammad Adnan Iqbal, M. A. I.; Bhatti, H. N.; Ghaffar, A. Cytotoxic, thrombolytic and antibacterial evaluation of synthesized substituted and un-substituted selenium-N-heterocyclic carbene adducts. J. Chem. Soc. Pakistan 2023, 45(128), 44–52; https://doi.org/10.52568/001198/jcsp/45.01.2023.Search in Google Scholar

Kanaoujiya, R.; Meenakshi; Srivastava, S.; Singh, R.; Mustafa, G. Recent advances and application of ruthenium complexes in tumor malignancy. Mater. Today: Proc. 2023, 72, 2822–2827; https://doi.org/10.1016/j.matpr.2022.07.098.Search in Google Scholar

Kapitza, S.; Pongratz, M.; Jakupec, M. A.; Heffeter, P.; Berger, W.; Lackinger, L.; Keppler, B. K.; Marian, B. Heterocyclic complexes of ruthenium (III) induce apoptosis in colorectal carcinoma cells. J. Cancer Res. Clin. Oncol. 2005, 131(2), 101–110; https://doi.org/10.1007/s00432-004-0617-0.Search in Google Scholar PubMed

Katheria, S. Ruthenium complexes as potential cancer cell growth inhibitors for targeted chemotherapy. ChemistrySelect 2022, 7(29), e202201645; https://doi.org/10.1002/slct.202201645.Search in Google Scholar

Khamis, Z. I.; Pang, X.; Cui, Z.; Sang, Q. X. A.; Zhang, J. Cytochrome P450-2D6: a novel biomarker in liver cancer health disparity. PLoS One 2021, 16(10), e0257072; https://doi.org/10.1371/journal.pone.0257072.Search in Google Scholar PubMed PubMed Central

Kostova, I. Ruthenium complexes as anticancer agents. Curr. Med. Chem. 2006, 13(9), 1085–1107; https://doi.org/10.2174/092986706776360941.Search in Google Scholar PubMed

Kuang, S.-M.; Cuttell, D. G.; McMillin, D. R.; Fanwick, P. E.; Walton, R. A. Synthesis and structural characterization of Cu (I) and Ni (II) complexes that contain the Bis [2-(diphenylphosphino) phenyl] ether ligand. Novel emission properties for the Cu (I) species. Inorg. Chem. 2002, 41(12), 3313–3322; https://doi.org/10.1021/ic0201809.Search in Google Scholar PubMed

Kundu, B. K.; Mukhopadhyay, S. Target based chemotherapeutic advancement of ruthenium complexes. Coord. Chem. Rev. 2021, 448, 214169; https://doi.org/10.1016/j.ccr.2021.214169.Search in Google Scholar

Larina, V.; Babich, O.; Zhikhreva, A.; Ivanova, S.; Chupakhin, E. The use of metal-organic frameworks as heterogeneous catalysts. Rev. Inorg. Chem. 2022; https://doi.org/10.1515/revic-2022-0020.Search in Google Scholar

Lazarević, T.; Rilak, A.; Bugarčić, Ž. D. Platinum, palladium, gold and ruthenium complexes as anticancer agents: current clinical uses, cytotoxicity studies and future perspectives. Eur. J. Med. Chem. 2017, 142, 8–31; https://doi.org/10.1016/j.ejmech.2017.04.007.Search in Google Scholar PubMed

Lee, S. L. C.; Rouhi, P.; Jensen, L. D.; Zhang, D.; Ji, H.; Hauptmann, G.; Ingham, P.; Cao, Y. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc. Natl. Acad. Sci. USA 2009, 106(46), 19485–19490; https://doi.org/10.1073/pnas.0909228106.Search in Google Scholar PubMed PubMed Central

Lee, S. Y.; Kim, C. Y.; Nam, T.-G. Ruthenium complexes as anticancer agents: a brief history and perspectives. Drug Des. Dev. Ther. 2020, 14, 5375; https://doi.org/10.2147/dddt.s275007.Search in Google Scholar PubMed PubMed Central

Li, Y.; Drabsch, Y.; Pujuguet, P.; Ren, J.; van Laar, T.; Zhang, L.; van Dam, H.; Clément-Lacroix, P.; Ten Dijke, P. Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models. Breast Cancer Res. 2015, 17(1), 1–16.10.1186/s13058-015-0537-8Search in Google Scholar PubMed PubMed Central

Li, Z. Y.; Shen, Q.; Mao, Z.; Tan, C. Rising interest in the development of metal complexes in cancer immunotherapy. Chem.--Asian J. 2022, 17(13), e202200270; https://doi.org/10.1002/asia.202200270.Search in Google Scholar PubMed

Lin, K.; Zhao, Z. Z.; Bo, H. B.; Hao, X. J.; Wang, J. Q. Applications of ruthenium complex in tumor diagnosis and therapy. Front. Pharmacol. 2018, 9, 1323; https://doi.org/10.3389/fphar.2018.01323.Search in Google Scholar PubMed PubMed Central

Liu, X.-W.; Li, J.; Li, H.; Zheng, K. C.; Chao, H.; Ji, L. N. Synthesis, characterization, DNA-binding and photocleavage of complexes [Ru (phen) 2 (6-OH-dppz)] 2+ and [Ru (phen) 2 (6-NO2-dppz)] 2+. J. Inorg. Biochem. 2005, 99(12), 2372–2380; https://doi.org/10.1016/j.jinorgbio.2005.09.004.Search in Google Scholar PubMed

Lord, C. J.; Ashworth, A. The DNA damage response and cancer therapy. Nature 2012, 481(7381), 287–294; https://doi.org/10.1038/nature10760.Search in Google Scholar PubMed

McGhie, B. S.; Aldrich-Wright, J. R. Photoactive and luminescent transition metal complexes as anticancer agents: a guiding light in the search for new and improved cancer treatments. Biomedicines 2022, 10(3), 578; https://doi.org/10.3390/biomedicines10030578.Search in Google Scholar PubMed PubMed Central

Meanwell, N. A. Improving drug design: an update on recent applications of efficiency metrics, strategies for replacing problematic elements, and compounds in nontraditional drug space. Chem. Res. Toxicol. 2016, 29(4), 564–616; https://doi.org/10.1021/acs.chemrestox.6b00043.Search in Google Scholar PubMed

Mejía, Y. R.; Romero Romero, F.; Basavanag Unnamatla, M. V.; Ballesteros Rivas, M. F.; Varela Guerrero, V. Metal-Organic Frameworks as bio- and heterogeneous catalyst supports for biodiesel production. Rev. Inorg. Chem. 2022, 43, 325–355; https://doi.org/10.1515/revic-2022-0014.Search in Google Scholar

Murillo, M. I.; Gaiddon, C.; Le Lagadec, R. Targeting of the intracellular redox balance by metal complexes towards anticancer therapy. Front. Chem. 2022, 10, 967337; https://doi.org/10.3389/fchem.2022.967337.Search in Google Scholar PubMed PubMed Central

Nagy, E. M.; Pettenuzzo, A.; Boscutti, G.; Marchiò, L.; Dalla Via, L.; Fregona, D. Ruthenium (II/III)‐Based compounds with encouraging antiproliferative activity against non‐small‐cell lung cancer. Chem.--Eur. J. 2012, 18(45), 14464–14472; https://doi.org/10.1002/chem.201202171.Search in Google Scholar PubMed

Ndagi, U.; Mhlongo, N.; Soliman, M. E. Metal complexes in cancer therapy–an update from drug design perspective. Drug Des. Dev. Ther. 2017, 11, 599; https://doi.org/10.2147/dddt.s119488.Search in Google Scholar PubMed PubMed Central

Nhukeaw, T.; Temboot, P.; Hansongnern, K.; Ratanaphan, A. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium (II) complexes containing chloro-substituted phenylazopyridine. BMC Cancer 2014, 14(1), 1–19; https://doi.org/10.1186/1471-2407-14-73.Search in Google Scholar PubMed PubMed Central

Nounou, M. I.; ElAmrawy, F.; Ahmed, N.; Abdelraouf, K.; Goda, S.; Syed-Sha-Qhattal, H. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer Basic Clin. Res. 2015, 9, 17–34. https://doi.org/10.4137/bcbcr.s29420.Search in Google Scholar

Núñez, C.; Estévez, S. V.; del Pilar Chantada, M. Inorganic nanoparticles in diagnosis and treatment of breast cancer. J. Biol. Inorg Chem. 2018, 23(3), 331–345; https://doi.org/10.1007/s00775-018-1542-z.Search in Google Scholar PubMed

Paprocka, R.; Wiese-Szadkowska, M.; Janciauskiene, S.; Kosmalski, T.; Kulik, M.; Helmin-Basa, A. Latest developments in metal complexes as anticancer agents. Coord. Chem. Rev. 2022, 452, 214307; https://doi.org/10.1016/j.ccr.2021.214307.Search in Google Scholar

Pfister, C. U.; Martoni, A.; Zamagni, C.; Lelli, G.; De Braud, F.; Souppart, C.; Duval, M.; Hornberger, U. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara®) in breast cancer patients. Biopharm Drug Dispos. 2001, 22(5), 191–197; https://doi.org/10.1002/bdd.273.Search in Google Scholar PubMed

Popolin, C. P.; Cominetti, M. R. A review of ruthenium complexes activities on breast cancer cells. Mini Rev. Med. Chem. 2017, 17(15), 1435–1441; https://doi.org/10.2174/1389557517666170206151218.Search in Google Scholar PubMed

Poynton, F. E.; Bright, S. A.; Blasco, S.; Williams, D. C.; Kelly, J. M.; Gunnlaugsson, T. The development of ruthenium (II) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications. Chem. Soc. Rev. 2017, 46(24), 7706–7756; https://doi.org/10.1039/c7cs00680b.Search in Google Scholar PubMed

Prachayasittikul, V.; Pingaew, R.; Nantasenamat, C.; Prachayasittikul, S.; Ruchirawat, S. Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinoline and uracil derivatives. Drug Des. Dev. Ther. 2014, 8, 1089; https://doi.org/10.2147/dddt.s67300.Search in Google Scholar PubMed PubMed Central

Prudent, J.; Popgeorgiev, N.; Gadet, R.; Deygas, M.; Rimokh, R.; Gillet, G. Mitochondrial Ca2+ uptake controls actin cytoskeleton dynamics during cell migration. Sci. Rep. 2016, 6(1), 1–13; https://doi.org/10.1038/srep36570.Search in Google Scholar PubMed PubMed Central

Qian, C.; Wang, J. Q.; Song, C. L.; Wang, L. L.; Ji, L. N.; Chao, H. The induction of mitochondria-mediated apoptosis in cancer cells by ruthenium (II) asymmetric complexes. Metallomics 2013, 5(7), 844–854; https://doi.org/10.1039/c3mt20270d.Search in Google Scholar PubMed

Qiu, K.; Wen, Y.; Ouyang, C.; Liao, X.; Liu, C.; Rees, T. W.; Zhang, Q.; Ji, L.; Chao, H. The stepwise photodamage of organelles by two-photon luminescent ruthenium (ii) photosensitizers. Chem. Commun. 2019, 55(75), 11235–11238; https://doi.org/10.1039/c9cc05962h.Search in Google Scholar PubMed

Rajendiran, V.; Karthik, R.; Palaniandavar, M.; Stoeckli-Evans, H.; Periasamy, V. S.; Akbarsha, M. A.; Srinag, B. S.; Krishnamurthy, H. Mixed-ligand copper (II)-phenolate complexes: effect of coligand on enhanced DNA and protein binding, DNA cleavage, and anticancer activity. Inorg. Chem. 2007, 46(20), 8208–8221; https://doi.org/10.1021/ic700755p.Search in Google Scholar PubMed

Ramadevi, P.; Singh, R.; Jana, S. S.; Devkar, R.; Chakraborty, D. Ruthenium complexes of ferrocene mannich bases: DNA/BSA interactions and cytotoxicity against A549 cell line. J. Photochem. Photobiol. Chem. 2015, 305, 1–10; https://doi.org/10.1016/j.jphotochem.2015.02.010.Search in Google Scholar

Raza, A.; Parveen, S.; Majeed, M. I.; Nawaz, H.; Javed, M. R.; Iqbal, M. A.; Rashid, N.; Haider, M. Z.; Ali, M. Z.; Sabir, A.; Mahmood ul Hasan, H.; Majeed, B. Surface-enhanced Raman spectral characterization of antifungal activity of selenium and zinc based organometallic compounds. Spectrochim. Acta Mol. Biomol. Spectrosc. 2023, 285, 121903; https://doi.org/10.1016/j.saa.2022.121903.Search in Google Scholar PubMed

Schreiber-Brynzak, E.; Klapproth, E.; Unger, C.; Lichtscheidl-Schultz, I.; Göschl, S.; Schweighofer, S.; Trondl, R.; Dolznig, H.; Jakupec, M. A.; Keppler, B. K. Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. Invest. N. Drugs 2015, 33(4), 835–847; https://doi.org/10.1007/s10637-015-0260-4.Search in Google Scholar PubMed

Shahzad, K.; Majid, A. S. A.; Khan, M.; Iqbal, M. A.; Ali, A. Recent advances in the synthesis of (99mTechnetium) based radio-pharmaceuticals. Rev. Inorg. Chem. 2021, 41(3), 151–198; https://doi.org/10.1515/revic-2020-0021.Search in Google Scholar

Shahzad, K.; Asad, M.; Asiri, A. M.; Irfan, M.; Iqbal, M. A. In-vitro anticancer profile of recent ruthenium complexes against liver cancer. Rev. Inorg. Chem. 2023, 43(1), 33–47; https://doi.org/10.1515/revic-2021-0040.Search in Google Scholar

Shakeri, A.; Panahi, Y.; Johnston, T. P.; Sahebkar, A. Biological properties of metal complexes of curcumin. Biofactors 2019, 45(3), 304–317; https://doi.org/10.1002/biof.1504.Search in Google Scholar PubMed

Shen, X.; Garces, L. J.; Ding, Y.; Laubernds, K.; Zerger, R. P.; Aindow, M.; Neth, E. J.; Suib, S. L. Behavior of H2 chemisorption on Ru/TiO2 surface and its application in evaluation of Ru particle sizes compared with TEM and XRD analyses. Appl. Catal. Gen. 2008, 335(2), 187–195; https://doi.org/10.1016/j.apcata.2007.11.017.Search in Google Scholar

Shen, J.; Kim, H. C.; Wolfram, J.; Mu, C.; Zhang, W.; Liu, H.; Xie, Y.; Mai, J.; Zhang, H.; Li, Z.; Guevara, M.; Mao, Z. W.; Shen, H. A liposome encapsulated ruthenium polypyridine complex as a theranostic platform for triple-negative breast cancer. Nano Lett. 2017, 17(5), 2913–2920; https://doi.org/10.1021/acs.nanolett.7b00132.Search in Google Scholar PubMed PubMed Central

Shum, J.; Leung, P.K.-K.; Lo, K.K.-W. Luminescent ruthenium (ii) polypyridine complexes for a wide variety of biomolecular and cellular applications. Inorg. Chem. 2019, 58(4), 2231–2247; https://doi.org/10.1021/acs.inorgchem.8b02979.Search in Google Scholar PubMed

Shutkov, I.; Antonets, A. A.; Tyurin, V. Y.; Milaeva, E. R.; Nazarov, A. A. Ruthenium (III) complexes of NAMI-A type with ligands based on lonidamine and bexarotene as antiproliferative agents. Russ. J. Inorg. Chem. 2021, 66(4), 502–509; https://doi.org/10.1134/s0036023621030177.Search in Google Scholar

Smith, C. A.; Sutherland-Smith, A. J.; Kratz, F.; Baker, E. N.; Keppler, B. H. Binding of ruthenium (III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses. J. Biol. Inorg Chem. 1996, 1(5), 424–431; https://doi.org/10.1007/s007750050074.Search in Google Scholar

Soriano-Giles, G.; Giles-Mazón, E. A.; Lopez, N.; Reinheimer, E.; Varela-Guerrero, V.; Ballesteros-Rivas, M. F. Metal organic frameworks (MOFS) as non-viral carriers for DNA and RNA delivery: a review. Rev. Inorg. Chem. 2022, 43, 201–219; https://doi.org/10.1515/revic-2022-0004.Search in Google Scholar

Stolyarova, E. D.; Mikhailov, A. A.; Ulantikov, A. A.; Eremina, J. A.; Klyushova, L. S.; Kuratieva, N. V.; Nadolinny, V. A.; Kostin, G. A. Blue-to-red light triggered nitric oxide release in cytotoxic/cytostatic ruthenium nitrosyl complexes bearing biomimetic ligands. J. Photochem. Photobiol. Chem. 2021, 421, 113520; https://doi.org/10.1016/j.jphotochem.2021.113520.Search in Google Scholar

Sudhindra, P.; Ajay Sharma, S.; Roy, N.; Moharana, P.; Paira, P. Recent advances in cytotoxicity, cellular uptake and mechanism of action of ruthenium metallodrugs: a review. Polyhedron 2020, 192, 114827; https://doi.org/10.1016/j.poly.2020.114827.Search in Google Scholar

Sumithaa, C.; Ganeshpandian, M. Half-Sandwich ruthenium arene complexes bearing clinically approved drugs as ligands: the importance of metal–drug synergism in metallodrug design. Mol. Pharm. 2023, 20(3), 1453–1479; https://doi.org/10.1021/acs.molpharmaceut.2c01027.Search in Google Scholar PubMed

Süss-Fink, G. Arene ruthenium complexes as anticancer agents. Dalton Trans. 2010, 39(7), 1673–1688; https://doi.org/10.1039/b916860p.Search in Google Scholar PubMed

Tan, C.; Lai, S.; Wu, S.; Hu, S.; Zhou, L.; Chen, Y.; Wang, M.; Zhu, Y.; Lian, W.; Peng, W.; Ji, L.; Xu, A. Nuclear permeable ruthenium (II) β-carboline complexes induce autophagy to antagonize mitochondrial-mediated apoptosis. J. Med. Chem. 2010, 53(21), 7613–7624; https://doi.org/10.1021/jm1009296.Search in Google Scholar PubMed

Tan, X.; Jiang, X.; He, Y.; Zhong, F.; Li, X.; Xiong, Z.; Li, Z.; Liu, X.; Cui, C.; Zhao, Q.; Xie, Y.; Yang, F.; Wu, C.; Shen, J.; Zheng, M.; Wang, Z.; Jiang, H. Automated design and optimization of multitarget schizophrenia drug candidates by deep learning. Eur. J. Med. Chem. 2020, 204, 112572; https://doi.org/10.1016/j.ejmech.2020.112572.Search in Google Scholar PubMed

Thota, S.; Rodrigues, D. A.; Crans, D. C.; Barreiro, E. J. Ru (II) compounds: next-generation anticancer metallotherapeutics? J. Med. Chem. 2018, 61(14), 5805–5821; https://doi.org/10.1021/acs.jmedchem.7b01689.Search in Google Scholar PubMed

Trondl, R.; Heffeter, P.; Kowol, C. R.; Jakupec, M. A.; Berger, W.; Keppler, B. K. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chem. Sci. 2014, 5, 2925–2932; https://doi.org/10.1039/c3sc53243g.Search in Google Scholar

Tulotta, C.; Stefanescu, C.; Beletkaia, E.; Bussmann, J.; Tarbashevich, K.; Schmidt, T.; Snaar-Jagalska, B. E. Inhibition of signaling between human CXCR4 and zebrafish ligands by the small molecule IT1t impairs the formation of triple-negative breast cancer early metastases in a zebrafish xenograft model. Dis. Models Mech. 2016, 9(2), 141–153; https://doi.org/10.1242/dmm.023275.Search in Google Scholar PubMed PubMed Central

Vincent, J. B.; Love, S. The binding and transport of alternative metals by transferrin. Biochim. Biophys. Acta Gen. Subj. 2012, 1820(3), 362–378; https://doi.org/10.1016/j.bbagen.2011.07.003.Search in Google Scholar PubMed

Wang, X.; Guo, Z. Targeting and delivery of platinum-based anticancer drugs. Chem. Soc. Rev. 2013, 42(1), 202–224; https://doi.org/10.1039/c2cs35259a.Search in Google Scholar PubMed

Wang, Z.; Li, J.; Lin, G.; He, Z.; Wang, Y. Metal complex-based liposomes: applications and prospects in cancer diagnostics and therapeutics. J. Contr. Release 2022, 348, 1066–1088; https://doi.org/10.1016/j.jconrel.2022.06.012.Search in Google Scholar PubMed

Wu, B.-Y.; Gao, L. H.; Duan, Z. M.; Wang, K. Z. Syntheses and DNA-binding studies of two ruthenium (II) complexes containing one ancillary ligand of bpy or phen:[Ru (bpy)(pp [2, 3] p) 2](ClO4) 2 and [Ru (phen)(pp [2, 3] p) 2](ClO4) 2. J. Inorg. Biochem. 2005, 99(8), 1685–1691; https://doi.org/10.1016/j.jinorgbio.2005.05.012.Search in Google Scholar PubMed

Yuan, R.-X.; Xiong, R. G.; Abrahams, B. F.; Lee, G. H.; Peng, S. M.; Che, C. M.; You, X. Z. A Cu (I) coordination polymer employing a nonsteroidal aromatase inhibitor letrozole as a building block. J. Chem. Soc., Dalton Trans. 2001(14), 2071–2073; https://doi.org/10.1039/b104880p.Search in Google Scholar

Zamora, A.; Denning, C. A.; Heidary, D. K.; Wachter, E.; Nease, L. A.; Ruiz, J.; Glazer, E. C. Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage. Dalton Trans. 2017, 46(7), 2165–2173; https://doi.org/10.1039/c6dt04405k.Search in Google Scholar PubMed

Zeng, L.; Chen, Y.; Liu, J.; Huang, H.; Guan, R.; Ji, L.; Chao, H. Ruthenium (II) complexes with 2-phenylimidazo [4, 5-f] [1, 10] phenanthroline derivatives that strongly combat cisplatin-resistant tumor cells. Sci. Rep. 2016, 6(1), 1–13; https://doi.org/10.1038/srep19449.Search in Google Scholar PubMed PubMed Central

Zeng, L.; Gupta, P.; Chen, Y.; Wang, E.; Ji, L.; Chao, H.; Chen, Z. S. The development of anticancer ruthenium (II) complexes: from single molecule compounds to nanomaterials. Chem. Soc. Rev. 2017, 46(19), 5771–5804; https://doi.org/10.1039/c7cs00195a.Search in Google Scholar PubMed PubMed Central

Zhang, Z.; Wu, Q.; Wu, X. H.; Sun, F. Y.; Chen, L. M.; Chen, J. C.; Yang, S. L.; Mei, W. J. Ruthenium (II) complexes as apoptosis inducers by stabilizing c-myc G-quadruplex DNA. Eur. J. Med. Chem. 2014, 80, 316–324; https://doi.org/10.1016/j.ejmech.2014.04.070.Search in Google Scholar PubMed

Zhao, X.; Li, L.; Yu, G.; Zhang, S.; Li, Y.; Wu, Q.; Huang, X.; Mei, W. Nucleus-enriched ruthenium polypyridine complex acts as a potent inhibitor to suppress triple-negative breast cancer metastasis in vivo. Comput. Struct. Biotechnol. J. 2019, 17, 21–30; https://doi.org/10.1016/j.csbj.2018.11.010.Search in Google Scholar PubMed PubMed Central